Reversible Cathepsin B Inhibitor Lead Series
Cathepsin B is an abundant and ubiquitously expressed cysteine peptidase involved in many pathological processes, such as inflammation, parasite infection and cancer. To date, most cathepsin B inhibitors are short peptides or small molecules that bind covalently to the enzyme, which is a generally unfavoured feature for drugs. A novel lead series of non-covalent cathepsin B inhibitors has been identified and characterized. Ease of synthesis and favourable properties like good solubility will allow further development and optimization for preclinical testing on a short timescale. Activity, selectivity, cytotoxicity and solubility data has been compiled for a series of about 50 compounds and an SAR has been established. Next steps will involve in vivo testing and further optimization of the lead series.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Solving the riddle of the sphingolipids in coronary artery disease
Weill Cornell Medicine investigators have uncovered a way to unleash in blood vessels the protective effects of a type of fat-related molecule known as a sphingolipid, suggesting a promising new…
Rocks with the oldest evidence yet of Earth’s magnetic field
The 3.7 billion-year-old rocks may extend the magnetic field’s age by 200 million years. Geologists at MIT and Oxford University have uncovered ancient rocks in Greenland that bear the oldest…
Decisive breakthrough for battery production
Storing and utilising energy with innovative sulphur-based cathodes. HU research team develops foundations for sustainable battery technology Electric vehicles and portable electronic devices such as laptops and mobile phones are…